The Plasmid DNA Manufacturing Market involves the production, purification and manipulation of Plasmid DNA, which is circular DNA present in bacteria and certain other organisms. Plasmid DNA is commonly used in molecular cloning to make copies of genes or to express genes in cells and organisms that do not normally contain those genes. They provide advantages like quick amplification in bacterial cells and flexibility in cloning gene fragments. With the rise in gene therapy and cell-based therapies, the need for pure, high-quality and GMP-compliant plasmid DNA has increased significantly.
The Global plasmid DNA manufacturing market Size is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga.
The demand for plasmid DNA is expected to increase substantially driven by rising need for gene and cell therapies. Advancements in gene therapy research and development along with increasing funding are further fueling the market growth.
New plasmid construction technologies like transposition, recombinational cloning and Gibson assembly have improved DNA construction efficiency significantly. Advancements like establishment of suspension cell culture systems for high-density plasmid production have helped achieve industrial scale production levels.
Market Trends
One key trend seen in the market is outsourcing of plasmid DNA manufacturing activities to specialized contract manufacturers. This is due to expertise required for development and production of gene therapy grade plasmid DNA. Another trend is use of single-use technologies which have enabled flexible production processes and reduced cleaning validation requirements.
Market Opportunities
Growing interest in development of gene therapy and gene-modified cell therapy products globally presents significant market opportunities. Establishment of specialized plasmid manufacturing facilities can help cater to the increasing demand. Adoption of continuous manufacturing and advanced process analytical technology presents opportunities to develop high yield and robust processes for plasmid DNA production.
Impact of COVID-19 on Plasmid DNA Manufacturing Market
The COVID-19 pandemic has significantly impacted the growth of the plasmid DNA manufacturing market. During the initial outbreak, supply chains were disrupted due to nationwide lockdowns imposed across countries. This led to reduced manufacturing activities and shortage of raw materials. Demand from the vaccine development sector also declined temporarily as research work was halted. However, post COVID-19, the demand is growing at a fast pace. Pharmaceutical companies are developing COVID-19 vaccines using plasmid DNA technology which requires large-scale plasmid DNA production for clinical trials and commercialization purposes. Greater investments are being made by governments and private sectors to boost manufacturing capacity of plasmid DNA to meet the rising demands. Market leaders are expanding their production facilities to cater to the increasing needs. Partnerships between players are also being witnessed to collaborate and develop vaccines rapidly. In the coming years, advances in plasmid DNA production technologies, continued R&D for coronavirus vaccines and therapeutics are expected to propel robust market growth.
Geographical Regions with Highest Plasmid DNA Manufacturing Market Value
North America dominates the plasmid DNA manufacturing market in terms of value, accounting for over 35% share. This is attributed to strong presence of key players, robust healthcare infrastructure and increasing funding for gene therapy research in the US. Government support through initiatives like Council of Canadian Academies and Plasmid DNA Production are also boosting the market in Canada. Europe holds the second largest share owing to highly developed pharmaceutical industry, rising prevalence of chronic diseases and approvals for cell and gene therapy products. Asia Pacific is anticipated to be the fastest growing regional market during the forecast period. Developing economies like China, India and South Korea are witnessing rising investments by international players to set up manufacturing facilities due to availability of low-cost skilled labor and resources.
Fastest Growing Regional Market for Plasmid DNA Manufacturing
The Asia Pacific region is projected to be the fastest growing market for plasmid DNA manufacturing during 2024-2030. This is due to increasing government focus on biopharmaceutical research and development activities. Countries like China, India, South Korea, Singapore, Australia and Japan are emerging as lucrative destinations for plasmid DNA production driven by their growing biotech sectors. Large patient pools, rising health expenditures by national governments are encouraging global companies to expand operations in Asia. Additionally, the presence of contract manufacturing organizations providing plasmid DNA development and manufacturing services at competitive prices is making the region highly attractive. Developments in gene therapy infrastructure along with growing plasmid DNA applications in vaccines, gene editing and disease modeling will propel Asia Pacific market growth significantly in the coming years.
Get More Insights on This Topic: https://www.pressreleasebulletin.com/plasmid-dna-manufacturing-market-demand-growth-and-regional-outlook-by-2030/
